Currently, multiple clinical trials are targeting the IL-1 family in hematological malignancies [8,9], examining predominantly the therapeutic values of either anakinra (antagonist of IL-1R) or canakinumab (IL-1β-neutralizing monoclonal antibody) [8,9]. This evidence concerns the gene IL1B and hematologic disorder.